Wyniki wyszukiwania - Biblioteka Nauki

1

Novel approach for utilization of poly(α-esters) and mesenchymal stem cells in vascular tissue engineering

100%

Sekula M. , Domalik-Pyzik P. , Morawska-Chochół A. , Bobis-Wozowicz S. , Madeja Z. , Chłopek J. , Zuba-Surma E.

Engineering of Biomaterials

|

2016

|

tom Vol. 19, no. 138 spec. iss.

23

2

Adipose-derived stem cells: a review of osteogenesis differentiation

100%

Skubis A. , Sikora B. , Zmarzły N. , Wojdas E. , Mazurek U.

Acta Universitatis Lodziensis. Folia Biologica et Oecologica

|

2016

|

tom 12

38-47

PL

Komórki macierzyste to komórki posiadające zdolność nieograniczonych podziałów oraz umiejętność do wielokierunkowego różnicowania. Mezenchymalne komórki macierzyste (MSC) to somatyczne komórki występujące w tkankach i narządach dorosłego organizmu takich jak: szpik kostny, tkanka tłuszczowa oraz mięśnie. Ulegają one różnicowaniu w kierunku komórek pochodzących z jednego listka zarodkowego jakim jest mezoderma. To pozwala na wykorzystanie ich w regeneracji chrząstki, kości lub wypełnienia ubytków tkanką tłuszczowa między innymi w chirurgi plastycznej. Obecnie głównym źródłem z którego pozyskiwano MSC był szpik kostny, jednak coraz szersze zastosowanie wykazuje tkanka tłuszczowa. Komórki z niej pochodzące wykazują takie same właściwości jak te pochodzące z szpiku kostnego, a procedura izolacji jest dużo mniej inwazyjna dla pacjenta. Bardzo często natomiast ich ilość jest nieporównywanie większa. Stąd też niniejsza praca porusza temat wykorzystania MSC z tkanki tłuszczowej w regeneracji tkanki kostnej.

EN

This review article provides an overview on adipose-derived stem cells (ADSCs) for implications in bone tissue regeneration. Firstly this article focuses on mesenchymal stem cells (MSCs) which are object of interest in regenerative medicine. Stem cells have unlimited potential for self-renewal and develop into various cell types. They are used for many therapies such as bone tissue regeneration. Adipose tissue is one of the main sources of mesenchymal stem cells (MSCs). Regenerative medicine intends to differentiate ADSC along specific lineage pathways to effect repair of damaged or failing organs. For further clinical applications it is necessary to understand mechanisms involved in ADSCs proliferation and differentiation. Second part of manuscript based on osteogenesis differentiation of stem cells. Bones are highly regenerative organs but there are still many problems with therapy of large bone defects. Sometimes there is necessary to make a replacement or expansion new bone tissue. Stem cells might be a good solution for this especially ADSCs which manage differentiate into osteoblast in in vitro and in vivo conditions.

3

Graphene-based substrates influence biological and functional properties of human umbilical cord-derived mesenchymal stem cells

100%

Sekuła M. , Karnas E. , Jagiełło J. , Noga S. , Adamczyk E. , Dżwigońska M. , Kmiotek K. , Baran M. , Madeja Z. , Lipińska L. , Zuba-Surma E.

Engineering of Biomaterials

|

2016

|

tom Vol. 19, no. 138 spec. iss.

24

4

Aqueous biological graphene based formulations for ink-jet printing

100%

Dybowska-Sarapuk Ł. , Rumiński S. , Wróblewski G. , Słoma M. , Młożniak A. , Kalaszczyńska I. , Lewandowska-Szumieł M. , Jakubowska M.

Polish Journal of Chemical Technology

|

2016

|

tom Vol. 18, nr 2

46--52

EN

The aim of the study was to produce heterophasic graphene nanoplatelets based formulation designed for ink-jet printing and biomedical applications. The compositions should meet two conditions: should be cytocompatible and have the rheological properties that allow to apply it with ink-jet printing technique. In view of the above conditions, the selection of suspensions components, such as binder, solvent and surfactants was performed. In the first stage of the research the homogeneity of the dispersion of nanoplatelets and their sedimentation behaviour in diverse solutions were tested. Subsequently, the cytotoxicity of each ink on human mesenchymal stem cells was examined using the Alamar Blue Test. At the same time the rheology of the resulting suspensions was tested. As a result of these tests the best ink composition was elaborated: water, polyethylene glycol, graphene nanoplatelets and the surfactant from DuPont company.

5

Adhesion, growth and osteogenic differentiation of human bone marrow mesenchymal stem cells on positively and negatively charged ferroelectric crystal surfaces

100%

Bacakova L. , Vandrovcova M. , Vanek P. , Petzelt J.

Engineering of Biomaterials

|

2016

|

tom Vol. 19, no. 138 spec. iss.

28

6

Mesenchymal stem cells for the treatment of complex perianal fistulas in patients with Crohn disease

88%

Borycka-Kiciak K. , Pietrzak A. , Kielar M. , Tarnowski W.

Polish Journal of Surgery

|

2020

|

tom 92(1)

38-47

EN

Treatment of perianal fistulizing Crohn’s disease is demanding and burdened with a high percentage of failures, which forces clinicians to search for new, more effective therapeutic options. One of these options is the use of adipose-derived mesenchymal stem cells in local administration. Due to their multipotentiality and complex mechanism of action, stem cells are the promising new therapeutic approach for the treatment-refractory complex perianal fistulas – demonstrating both high efficacy and a favorable safety profile. The paper presents current knowledge on the mechanisms of action and manner of administration of mesenchymal stem cells, as well as the effectiveness and safety of their use in the treatment of perianal Crohn’s disease based on available literature.

7

Izolacja i hodowla mezenchymalnych komórek macierzystych szpiku kostnego w warunkach in vitro – techniczne aspekty

88%

Lange M. , Borowik A.

Edukacja Biologiczna i Środowiskowa

|

2014

|

nr 3

18-24

EN

Multipotent mesenchymal stromal cells also known as mesenchymal stem cells according to the signal from the damaged tissue have the ability to differentiate into several types of specialized cells forming tissues of mesodermal origin such as bone, cartilage, tendon, skeletal muscle or adipose tissue. This ability of MSC is used in regenerative medicine. For the clinical and experimental purposes in order to increase the amount of MSC their ability to proliferate in vitro is used. The best-known source of mesenchymal stem cells is the adipose tissue and bone marrow which is the most common source material used for primary culture. This paper presents the next steps of culturing mesenchymal stem cells in vitro.

8

Immunophenotypic characteristics and karyotype analysis of bone marrow-derived mesenchymal stem cells of rabbits duringin vitro cultivation

75%

Mazurkevych A. , Kharkevych Y. , Jakubczak A. , Gryzinska M. , Malyuk M. , Bezdieniezhnykh N. , Starodub L.

|

2017

|

nr 4

9

Current status and future prospects of genome-scale metabolic modeling to optimize the use of mesenchymal stem cells in regenerative medicine and biomaterials

75%

Sigurjonsson O. E.

Engineering of Biomaterials

|

2020

|

tom Vol. 23, no. 158 spec. iss.

7

EN

Mesenchymal stem cells are a promising source for externally grown tissue replacements and patient-specific immunomodulatory treatments. This promise has not yet been fulfilled in part due to production scaling issues and the need to maintain the correct phenotype after reimplantation. One aspect of extracorporeal growth that may be manipulated to optimize cell growth and differentiation is metabolism. The metabolism of MSCs changes during and in response to differentiation and immunomodulatory changes. MSC metabolism may be linked to functional differences but how this occurs and influences MSC function remains unclear. Understanding how MSC metabolism relates to cell function is however important as metabolite availability and environmental circumstances in the body may affect the success of implantation. Genome-scale constraint based metabolic modelling can be used as a tool to fill gaps in knowledge of MSC metabolism, acting as a framework to integrate and understand various data types (e.g., genomic, transcriptomic and metabolomic). These approaches have long been used to optimize the growth and productivity of bacterial production systems and are being increasingly used to provide insights into human health research. Production of tissue for implantation using MSCs requires both optimized production of cell mass and the understanding of the patient and phenotype specific metabolic situation. This review considers the current knowledge of MSC metabolism and how it may be optimized along with the current and future uses of genome scale constraint based metabolic modelling to further this aim.

10

Potential therapeutic application of mesenchymal stem cells in COVID-19 complications

75%

Kolanko E. , Mazurski A. , Czekaj P.

Medycyna Pracy

|

2021

|

tom 72

|

nr 6

693-700

EN

Mesenchymal stem cells (MSCs) have remarkable immunomodulatory properties, low immunogenicity, and paracrine properties as well as the ability to differentiate into multiple cell lines. These properties make them potential candidates for clinical applications in the treatment of neurodegenerative, cardiovascular, and lung diseases, which may be occupational diseases. Preclinical studies using experimental animal models have demonstrated regenerative properties of MSCs in diseases such as silicosis and occupational asthma. Currently, treatment of the novel disease COVID-19 could be enhanced by using MSC therapies. This disease affects many professional groups with great intensity and its consequences might be considered as an occupational disease. It is a significant public health problem and a therapeutic challenge. Despite the development of vaccines against COVID-19, there is growing concern about the emergence of new mutations of the SARS-CoV-2 virus in addition to the known alpha, beta, gamma, and delta variants. There is still no effective COVID-19 treatment and the existing ones only play a supporting role. MSCs offer treatment possibilities as an alternative or complementary therapy. The clinical trials to date using MSCs in patients with COVID-19 give hope for the safe and effective use of this stem cell population.

11

Leczenie sterydoopornej ostrej choroby przeszczep przeciwko gospodarzowi

63%

Rzepecki P. , Gawroński K. , Młot B. , Oborska S. , Pielichowski W. , Waśko-Grabowska A.

Current Gynecologic Oncology

|

2011

|

tom 9

|

nr 4

253-263

EN

Use of allogeneic hematopoietic stem cell transplantation is increasing continuously as a consequence of continuing progress of medical techniques, allowing implementation of this procedure even in patients where previously it was considered contraindicated. It is successfully used in the treatment of both several hematologic malignancies and other conditions. Still, a major concern remains the development of graft-versus-host disease (GvHD) as a complication of this kind of therapy. Treatment of choice in acute forms of stage II-IV GvHD are steroids (prednisolone, 1-2 mg/kg/d) combined with calcineurin inhibitors (cyclosporine A or tacrolimus). Steroid-resistant patients constitute a considerable therapeutic challenge, as they require enhanced immunosuppression. Standard management of these patients depends on experiences of particular center and usually an individual therapeutic strategy is warranted. No controlled clinical trials are available, documenting a favorable effect on survival of a particular salvage procedure in the setting of a steroid-resistant GvHD. In this situation, the following agents may be used: mycophenolate mofetil, methotrexate, pentostatin, mTOR inhibitors, anti-TNF-α and anti-IL-2 antibodies as well as mono- and polyclonal anti-T-lymphocyte antibodies. Non-pharmacological options include the use of extracorporeal photopheresis and infusion of allogeneic mesenchymal stem cells. In order to improve its effectiveness, salvage therapy should be instituted as quickly as possible, at best during the first 2 weeks after diagnosis of GvHD. Nevertheless, overall effectiveness and toxicity of most therapeutic modalities are far from satisfactory. Current research focuses on regulatory T-lymphocytes and small molecules affecting signal transmission between antigen-presenting cells and effector cells.

PL

Zastosowanie przeszczepiania alogenicznych komórek macierzystych krwiotworzenia stale wzrasta z uwagi na stały postęp technik medycznych, pozwalających na kwalifikację do wykonania tej procedury u chorych, którzy uprzednio mieli do niej przeciwwskazania. Jest ona z powodzeniem stosowana w leczeniu wielu nowotworów hematologicznych oraz innych schorzeń. Nadal poważnym problemem pozostaje rozwój choroby przeszczep przeciwko gospodarzowi (GvHD) jako powikłanie użycia tej formy terapii. Leczeniem z wyboru ostrej postaci GvHD w stopniu II-IV są glikokortykoidy (prednizolon) w dawce 1-2 mg/kg/dziennie, w połączeniu z inhibitorami kalcyneuryny (cyklosporyna A lub takrolimus). Chorzy stery-dooporni stanowią bardzo poważny problem terapeutyczny, wymagają bowiem nasilenia immunosupresji. Standard postępowania u tych pacjentów zależy od doświadczeń ośrodka leczącego i zazwyczaj obowiązuje indywidualne podejście do chorego. Brakuje kontrolowanych badań klinicznych udowadniających wpływ na przeżycie konkretnego postępowania ratunkowego w leczeniu sterydoopornej ostrej GvHD. Można zastosować w tej sytuacji: kwas mykofenolowy, metotreksat, cyklofosfamid, pentostatynę, inhibitory mTOR, przeciwciała przeciwko TNF-a czy IL-2 oraz mono- i poliklonalne przeciwciała skierowane przeciwko limfocytom T. Opcje niefarmakologiczne obejmują użycie zewnątrzustrojowej fotote-rapii czy alogenicznych mezenchymalnych komórek macierzystych. W celu poprawy jego skuteczności leczenie ratunkowe w przypadku stwierdzenia sterydooporności powinno być zastosowane jak najszybciej, najlepiej w ciągu 2 tygodni od rozpoznania GvHD. Niemniej jednak ogólna skuteczność i toksyczność większości podejść terapeutycznych są niezadowalające. Przyszłość to zastosowanie regulatorowych limfocytów T czy użycie małych cząsteczek wpływających na przekazywanie sygnału pomiędzy komórkami prezentującymi antygen a komórkami efektorowymi.

12

Wpływ materiałów tlenkowych syntezowanych metodą zol-żel na adhezję mezenchymalnych komórek macierzystych

63%

Marycz K. , Krzak-Roś J. , Śmieszek A. , Grzesiak J. , Donesz-Sikorska A.

Przemysł Chemiczny

|

2013

|

tom T. 92, nr 6

1097--1100

13

Ocena wpływu nanocząstek tlenku żelaza na rozmieszczenie mezenchymalnych komórek macierzystych hodowanych w obecności statycznego pola magnetycznego

63%

Marędziak M. , Śmieszek A. , Basińska K. , Kornicka K.

Przemysł Chemiczny

|

2015

|

tom T. 94, nr 9

1598-1601

PL

Porównano wpływ różnych kombinacji dodatku nanocząstek żelaza i hodowli w obecności statycznego pola magnetycznego na wzrost i dystrybucję mezenchymalych komórek macierzystych. Oceniono również, czy dodatek tlenku żelaza umożliwia przyciąganie komórek wzdłuż przebiegu linii pola magnetycznego.

EN

Fe2O3 nanoparticles were pptd. with NH3 from aq. soln. of Fe(NO3)2, dispersed in UV field and added to a mesenchymal stem cell culture to move the cells in magnetic field. The orientation of the cells in magnetic field was obsd.

14

Investigation of human mesenchymal stem cells culture on nanofibrous polyurethane scaffolds and films

63%

Çelebi-Saltık B. , Öteyaka M. Ö.

Journal of Achievements in Materials and Manufacturing Engineering

|

2014

|

tom Vol. 64, nr 2

53--61

EN

Purpose: of this study was to evaluate whether electrospun porous nanofibrous scaffold of polyurethane (PU) with low and high beads accommodate the viability and growth of human bone marrow mesenchymal stem cells (hBM MSCs) in comparison with flat surface (Polypropylen). Design/methodology/approach: To our knowledge, the influence of the beads density on nanofibrous scaffold has never been investigated. For this purpose, we electrospun PU to fabric two porous nanofiber scaffolds with less and high density beads to enhance cells attachment and proliferation of hBM MSCs. Moreover, those surfaces were compared to a flat surface (PP). The samples were studied using scanning electron microscopy (SEM), Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) and static contact angle measurement. Findings: The characterization of the samples revealed that hydrophilic surface of high quantity nanofiber with fewer beads scaffolds (LBNF-PU) had less nanofiber with higher quantity of beads that were overlapped on each other firmly compared to low quantity nanofiber with more beads scaffolds (HBNF-PU). MSCs cell morphology on both HBNF-PU and LBNF-PU nanofibrous scaffolds and flat surface was different; it was observed elongated cell shape for LBNF-PU and flat surface and rounded cell shape for HBNF-PU. Live/dead studies confirmed cell viabilities on flat and nanostructured surfaces. Cells expansion on Polypropylen and nanofibrous scaffolds were increased until 7 days of culture. Research limitations/implications: The randomly nanofiber scaffold limited the growth of human bone marrow mesenchymal stem cells (hBM MSCs). The aligned nanofiber scaffold will be evaluated at next investigation. Originality/value: Nanofibrous scaffold have recently draw attention for potential applications in small vascular replacement. Human bone marrow mesenchymal stem cells (hBM MSCs) growth on porous nanofibrous scaffolds is a promising strategy for tissue engineering. The influence of the beads density on nanofibrous scaffold has never been investigated. For this purpose, we electrospun PU to fabric two porous nanofiber scaffolds with less and high density beads to enhance cells attachment and proliferation of hBM MSCs.

15

Brachyterapia o wysokiej mocy dawki u chorych na raka szyjki macicy

51%

Żółciak-Siwińska A. , Jońska-Gmyrek J. , Staniaszek J. , Kawczyńska M. , Kulik A.

Current Gynecologic Oncology

|

2011

|

tom 9

|

nr 4

264-271

EN

Selection of optimal treatment modality in a patient with cervical cancer depends on FIGO clinical stage. At stages IB2-IVA, the cornerstone of treatment is radiochemotherapy. As first step, patients undergo irradiation from external fields combined with chemotherapy (cisplatin, 40 mg/m2, QW). Brachytherapy is used as second-line treatment – an essential component thereof – enabling delivery of high dose of radiation to both genital organs and tumor. Quality of this treatment directly correlates with local control of the disease, long-term overall survival and quality of life of patients after completion of therapy. The paper presents current principles of high dose rate (HDR) brachytherapy in cervical cancer patients. Discussed are principles of two-dimensional (2D) planning, used to date in about 50% of brachytherapy centers worldwide, as well as three-dimensional (3D) magnetic resonance (MR)-based planning. As availability of MR in ours and many other oncology centers is limited, a computed tomography-based modification of gynecologic recommendations GIN GEC ESTRO has been suggested. Therapeutic areas are defined: high-risk clinical target volume (HR CTV) and intermediate risk clinical target volume (IR CTV) which may be safely contoured based on clinical exam and CT study, when no MRI is available. Acceptable doses for critical organs are listed. Based on own experience, indications and limitations for use of intraparenchymal (interstitial) and intracavitary applications were developed.

PL

Wybór metody leczenia chorych na raka szyjki macicy jest uzależniony od stopnia zaawansowania, ocenionego według klasyfikacji FIGO (International Federation of Gynecology and Obstetrics). Zasadniczą metodą leczenia chorych na raka szyjki macicy w stopniach zaawansowania IB2-IVA jest radiochemioterapia. W pierwszym etapie przeprowadzane jest napromienianie z pól zewnętrznych wraz z chemioterapią z zastosowaniem cisplatyny w dawce 40 mg/m2, raz w tygodniu. W kolejnym etapie leczenia stosuje się brachyterapię. Brachyterapia jest istotną częścią leczenia, umożliwiającą podanie wysokiej dawki na narząd rodny wraz z guzem, a jakość tego leczenia ma wpływ na kontrolę miejscową nowotworu (LC), przeżycia odległe (OS), jak również na jakość życia chorych po zakończeniu terapii. W pracy przedstawiono zasady obowiązujące współcześnie podczas leczenia brachyterapią o wysokiej mocy dawki (high dose rate brachytherapy, HDR) u chorych na raka szyjki macicy. Opisano zasady planowania w systemie dwuwymiarowym (2D), stosowanym do dzisiaj mniej więcej w połowie ośrodków brachyterapii na świecie, oraz planowania w systemie trójwymiarowym (3D) na podstawie rezonansu magnetycznego (MR). Ponieważ dostępność MR w naszym i wielu ośrodkach onkologicznych jest utrudniona, zaproponowano modyfikację rekomendacji GIN (Gynaecological) GEC ESTRO dla potrzeb planowania, opierając się na tomografii komputerowej. Zdefiniowano obszary terapeutyczne: HR CTV (high-risk clinical target volume), IR CTV (intermediate risk clinical target volume), jakie można bezpiecznie konturować, opierając się na badaniu klinicznym i TK, przy braku MR. Opisano dopuszczalne dawki dla narządów krytycznych. Na podstawie własnych doświadczeń opracowano wskazania i ograniczenia w zastosowaniu aplikacji śródtkankowych i śródjamowych.